CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.84BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.78xvs all stocks
52-Week Change
436.05%vs all stocks
Market Capitalization
7.84BUSDvs all stocks (USD)
Enterprise Value
7.08BUSDvs all stocks (USD)
Forward P/E
-30.21xvs Biotechnology peers
Price to Book (MRQ)
5.84xvs Biotechnology peers
Enterprise to EBITDA
-18.73xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.65%vs Biotechnology peers
Return on Equity (TTM)
-38.86%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 28, 2026Gross Profit (TTM)
-290.71MUSDvs all stocks (USD)
EBITDA (TTM)
-378.05MUSDvs all stocks (USD)
Net Income (TTM)
-339.13MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-305.08MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-199.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-326.20MUSDvs all stocks (USD)
Pre-tax Income
-303.27MUSDFY2025 · Dec 31, 2025Net Income
-303.27MUSDFY2025 · Dec 31, 2025EBIT
-326.20MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-326.06MUSDFY2025 · Dec 31, 2025Research & Development
267.12MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
59.08MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-303.27MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-257.32MUSDFY2025 · Dec 31, 2025Free Cash Flow
-257.37MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
357.75MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-303.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
140.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
33.94MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
12.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-56.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-623.81MUSDFY2025 · Dec 31, 2025Sale of Investments
312.72MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-311.15MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.09MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
688.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
27.92MSharesUpdated Sep 28, 2026Float Shares
24.08MSharesUpdated Sep 28, 2026Shares Short
3.80MSharesUpdated Sep 28, 2026Short Ratio
11.90daysvs all stocks
Short % of Shares Outstanding
13.63%vs all stocks
% Held by Insiders
0.28%vs all stocks
% Held by Institutions
123.20%vs all stocks
Total Cash (MRQ)
758.55MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
27.17USDUpdated Sep 28, 2026Total Debt (MRQ)
1.09MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0008xvs Biotechnology peers
Current Ratio (MRQ)
15.73xvs Biotechnology peers
Book Value per Share (MRQ)
48.04USDUpdated Sep 28, 2026Total Assets
937.91MUSDvs all stocks (USD)
Total Current Assets
610.91MUSDFY2025 · Dec 31, 2025Total Liabilities
59.77MUSDFY2025 · Dec 31, 2025Total Non-current Assets
327.00MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
59.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
357.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
242.00MUSDFY2025 · Dec 31, 2025Accounts Payable
24.63MUSDFY2025 · Dec 31, 2025Short-term Debt
110.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.14BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
878.14MUSDvs all stocks (USD)
52-Week Low
50.23USDUpdated Sep 28, 202652-Week High
392.70USDUpdated Sep 28, 202652-Week Change
436.05%vs all stocks
Beta
2.78xvs all stocks
50-Day MA
336.23USDUpdated Sep 28, 2026200-Day MA
316.09USDUpdated Sep 28, 2026Avg 10-Day Volume
562.58KSharesUpdated Sep 28, 2026Avg 30-Day Volume
400.11KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-12.97USDUpdated Sep 28, 2026Other Income / Expense
22.93MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 258
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 35,799,263.917
Market cap is $7.84B, above the global median of $1.15BNotable
Market cap (USD): 7,839,374,230Global Median: 1,150,342,212.262
Companies that share the same coordination system — how they create, deliver, or capture value.
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
ALK-Abello A/S
Tier 1ProductionApproval-Gated PipelineRule
Asymchem Laboratories (Tianjin) Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Spyre Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grifols, S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Demant A/S
Tier 1ProductionApproval-Gated PipelineFlowRule
InnoCare Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Delixi New Energy Technology Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Zhejiang Great Shengda Packaging Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Xiamen Solex High-Tech Industries Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity